If FDA officials were looking for clear guidance on adequacy of the current efficacy standard for novel naloxone products, they may have walked away from an Oct. 5 advisory committee meeting disappointed.
Members of the agency’s Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management advisory panels were highly...





